Tanshinone II is a potent candidate for treatment of lipopolysaccharide-induced acute lung injury in rat model

  • Authors:
    • Ling Li
    • Yong‑Gang Zhang
    • Yu‑Fei Tan
    • Jing‑Jing Zhao
    • Hua‑Ru Zhang
    • Bing Zhao
  • View Affiliations

  • Published online on: December 11, 2017     https://doi.org/10.3892/ol.2017.7581
  • Pages: 2550-2554
Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )


Abstract

The present study aimed to investigate the effect of tanshinone II, isolated from Salvia miltiorrhiza Bunge, on lipopolysaccharide (LPS)‑induced acute lung injury (ALI) in rats. Male Sprague‑Dawley rats were divided into three groups: Control, LPS and tanshinone II. Animals in the tanshinone II and LPS groups were administered 10 mg/kg LPS, whereas those in the control group received an equal volume of normal saline. Tanshinone II treatment group were injected with 30 nm/kg tanshinone II at 1 h after LPS administration. The results revealed that LPS administration increased the bronchoalveolar lavage fluid protein concentration significantly compared with the control group. However, tanshinone II treatment significantly inhibited the LPS‑induced increase in protein level. Treatment of the LPS‑administered rats with tanshinone II prevented the formation of pulmonary edema, which was evidenced by low values for wet to dry lung weight ratio. The activity of myeloperoxidase and expression of malondialdehyde were significantly lower in lung homogenates from the tanshinone II group compared with the LPS group. Furthermore, tanshinone II treatment inhibited the expression of tumor necrosis factor‑α and interleukin‑6 in the blood plasma. Tissue sections of the tanshinone II group exhibited normal morphology and absence of neutrophil accumulation. However, in the LPS group, neutrophils accumulated and penetrated into the pulmonary tissues. These results suggested that tanshinone II protects the rats from LPS‑induced ALI. Therefore tanshinone II may have clinical applications in the treatment of ALI.
View Figures
View References

Related Articles

Journal Cover

February-2018
Volume 15 Issue 2

Print ISSN: 1792-1074
Online ISSN:1792-1082

Sign up for eToc alerts

Recommend to Library

Copy and paste a formatted citation
x
Spandidos Publications style
Li L, Zhang YG, Tan YF, Zhao JJ, Zhang HR and Zhao B: Tanshinone II is a potent candidate for treatment of lipopolysaccharide-induced acute lung injury in rat model. Oncol Lett 15: 2550-2554, 2018
APA
Li, L., Zhang, Y., Tan, Y., Zhao, J., Zhang, H., & Zhao, B. (2018). Tanshinone II is a potent candidate for treatment of lipopolysaccharide-induced acute lung injury in rat model. Oncology Letters, 15, 2550-2554. https://doi.org/10.3892/ol.2017.7581
MLA
Li, L., Zhang, Y., Tan, Y., Zhao, J., Zhang, H., Zhao, B."Tanshinone II is a potent candidate for treatment of lipopolysaccharide-induced acute lung injury in rat model". Oncology Letters 15.2 (2018): 2550-2554.
Chicago
Li, L., Zhang, Y., Tan, Y., Zhao, J., Zhang, H., Zhao, B."Tanshinone II is a potent candidate for treatment of lipopolysaccharide-induced acute lung injury in rat model". Oncology Letters 15, no. 2 (2018): 2550-2554. https://doi.org/10.3892/ol.2017.7581